메뉴 건너뛰기




Volumn 29, Issue 6, 2011, Pages 1475-1481

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Author keywords

Bortezomib; Gastric cancer; Nuclear factor kB (NF KB); Proteasome

Indexed keywords

BORTEZOMIB; CYCLIN D1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21; PROTEIN P53; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

EID: 84856031653     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9474-7     Document Type: Article
Times cited : (45)

References (39)
  • 2
    • 70350204423 scopus 로고    scopus 로고
    • Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
    • Annual Proceedings, Orlando, FL, USA. May 29th-June 2nd; Abstract #LBA 4509
    • Van Cutsem E, Kang K, Chung H et al (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). American Society of Clinial Oncology, Annual Proceedings, Orlando, FL, USA. May 29th-June 2nd; Abstract #LBA 4509
    • (2009) American Society of Clinial Oncology
    • Van Cutsem, E.1    Kang, K.2    Chung, H.3
  • 3
    • 70450209516 scopus 로고    scopus 로고
    • Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial
    • Orlando, FL, 29 May-2 June 2009; Abstract #4556
    • Bang Y, Chung H, Xu J et al (2009) Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL, 29 May-2 June 2009; Abstract #4556
    • (2009) Amercan Society of Clinical Oncology, Annual Proceedings
    • Bang, Y.1    Chung, H.2    Xu, J.3
  • 4
    • 0036083396 scopus 로고    scopus 로고
    • The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction
    • Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428 (Pubitemid 34654457)
    • (2002) Physiological Reviews , vol.82 , Issue.2 , pp. 373-428
    • Glickman, M.H.1    Ciechanover, A.2
  • 5
    • 0037514596 scopus 로고    scopus 로고
    • Clinical update: Proteasome inhibitors in solid tumors
    • Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(Suppl 1):41-48
    • (2003) Cancer Treat Rev , vol.29 , Issue.1 SUPPL. , pp. 41-48
    • Lenz, H.J.1
  • 6
    • 0038189917 scopus 로고    scopus 로고
    • Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib
    • Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21-31
    • (2003) Cancer Treat Rev , vol.29 , Issue.1 SUPPL. , pp. 21-31
    • Cusack, J.C.1
  • 7
    • 33745298519 scopus 로고    scopus 로고
    • Nuclear factor-κB in cancer development and progression
    • DOI 10.1038/nature04870, PII NATURE04870
    • Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436 (Pubitemid 44050137)
    • (2006) Nature , vol.441 , Issue.7092 , pp. 431-436
    • Karin, M.1
  • 11
    • 34548357028 scopus 로고    scopus 로고
    • Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells
    • DOI 10.1097/CAD.0b013e32808bf9d8, PII 0000181320070700000007
    • Fujita T, Doihara H, Washio K et al (2007) Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 18:677-686 (Pubitemid 47343660)
    • (2007) Anti-Cancer Drugs , vol.18 , Issue.6 , pp. 677-686
    • Fujita, T.1    Doihara, H.2    Washio, K.3    Ino, H.4    Murakami, M.5    Naito, M.6    Shimizu, N.7
  • 12
    • 43849086302 scopus 로고    scopus 로고
    • Effects of the proteasome inhibitor bortezomib alone, and in combination with chemotherapeutic agents in gastric cancer cell lines
    • Bae SH, Ryoo HM, Kim MK et al (2008) Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 19:1027-1032 (Pubitemid 351802676)
    • (2008) Oncology Reports , vol.19 , Issue.4 , pp. 1027-1032
    • Bae, S.H.1    Ryoo, H.-M.2    Kim, M.K.3    Lee, K.H.4    Sin, J.-I.5    Hyun, M.S.6
  • 13
    • 0033733319 scopus 로고    scopus 로고
    • Cancer of the esophagogastric junction
    • Stein HJ, Feith M, Siewert JR (2000) Cancer of the esophagogastric junction. Surg Oncol 9:35-41
    • (2000) Surg Oncol , vol.9 , pp. 35-41
    • Stein, H.J.1    Feith, M.2    Siewert, J.R.3
  • 15
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 17
    • 2942720648 scopus 로고    scopus 로고
    • Expression profiling of colorectal carcinomas using tissue microarrays: Cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis
    • Prall F, Ostwald C, Nizze H, Barten M (2004) Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis. Appl Immunohistochem Mol Morphol 12:111-121 (Pubitemid 38788759)
    • (2004) Applied Immunohistochemistry and Molecular Morphology , vol.12 , Issue.2 , pp. 111-121
    • Prall, F.1    Ostwald, C.2    Nizze, H.3    Barten, M.4
  • 23
    • 77449083128 scopus 로고    scopus 로고
    • Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade ((R))) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
    • Li T, Ho L, Piperdi B et al (2009) Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade ((R))) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 11:11
    • (2009) Lung Cancer , vol.11 , pp. 11
    • Li, T.1    Ho, L.2    Piperdi, B.3
  • 25
    • 33646781960 scopus 로고    scopus 로고
    • Targeting the ubiquitinproteasome pathway in breast cancer therapy
    • Dees EC, Orlowski RZ (2006) Targeting the ubiquitinproteasome pathway in breast cancer therapy. Future Oncol 2:121-135
    • (2006) Future Oncol , vol.2 , pp. 121-135
    • Dees, E.C.1    Orlowski, R.Z.2
  • 26
    • 4644248931 scopus 로고    scopus 로고
    • Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
    • DOI 10.1158/1078-0432.CCR-04-0422
    • Shah MH, Young D, Kindler HL et al (2004) Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10:6111-6118 (Pubitemid 39287516)
    • (2004) Clinical Cancer Research , vol.10 , Issue.18 , pp. 6111-6118
    • Shah, M.H.1    Young, D.2    Kindler, H.L.3    Webb, I.4    Kleiber, B.5    Wright, J.6    Grever, M.7
  • 27
    • 70349754173 scopus 로고    scopus 로고
    • A phase II evaluation of bortezomib in the treatment of recurrent platinumsensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
    • Aghajanian C, Blessing JA, Darcy KM et al (2009) A phase II evaluation of bortezomib in the treatment of recurrent platinumsensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115:215-220
    • (2009) Gynecol Oncol , vol.115 , pp. 215-220
    • Aghajanian, C.1    Blessing, J.A.2    Darcy, K.M.3
  • 29
    • 73449130242 scopus 로고    scopus 로고
    • Oncogenic pathway combinations predict clinical prognosis in gastric cancer
    • Ooi CH, Ivanova T, Wu J et al (2009) Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genetics 5:1-13
    • (2009) PLoS Genetics , vol.5 , pp. 1-13
    • Ooi, C.H.1    Ivanova, T.2    Wu, J.3
  • 32
    • 52649173202 scopus 로고    scopus 로고
    • Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFRindependent mitogenic kinase signaling pathways in pancreatic cancer cells
    • Sloss CM, Wang F, Liu R et al (2008) Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFRindependent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 14:5116-5123
    • (2008) Clin Cancer Res , vol.14 , pp. 5116-5123
    • Sloss, C.M.1    Wang, F.2    Liu, R.3
  • 35
    • 0036690648 scopus 로고    scopus 로고
    • PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis
    • Ling YH, Liebes L, Ng B et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841-849
    • (2002) Mol Cancer Ther , vol.1 , pp. 841-849
    • Ling, Y.H.1    Liebes, L.2    Ng, B.3
  • 36
    • 0032510958 scopus 로고    scopus 로고
    • Superfolding of the partially unfolded core-glycosylated intermediate of human p-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions
    • DOI 10.1074/jbc.273.24.14671
    • Loo TW, Clarke DM (1998) Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem 273:14671-14674 (Pubitemid 28272748)
    • (1998) Journal of Biological Chemistry , vol.273 , Issue.24 , pp. 14671-14674
    • Loo, T.W.1    Clarke, D.M.2
  • 37
    • 0035328584 scopus 로고    scopus 로고
    • Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition
    • Cusack JC Jr, Liu R, Houston M et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535-3540 (Pubitemid 32694955)
    • (2001) Cancer Research , vol.61 , Issue.9 , pp. 3535-3540
    • Cusack Jr., J.C.1    Liu, R.2    Houston, M.3    Abendroth, K.4    Elliott, P.J.5    Adams, J.6    Baldwin Jr., A.S.7
  • 38
    • 67349263502 scopus 로고    scopus 로고
    • Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA)
    • Orlando, FL, USA, 15-17 January 2007
    • Ocean AJ, Schnoll-Sussman F, Chen XE et al (2007) Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2007
    • (2007) Gastrointestinal Cancer Symposium
    • Ocean, A.J.1    Schnoll-Sussman, F.2    Chen, X.E.3
  • 39
    • 43049090496 scopus 로고    scopus 로고
    • Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esopahgeal, gastric, and gastroesophageal cancer
    • Jatoi A, Dakhil SR, Foster NR et al (2008) Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esopahgeal, gastric, and gastroesophageal cancer. J Thorac Oncol 3:516-520
    • (2008) J Thorac Oncol , vol.3 , pp. 516-520
    • Jatoi, A.1    Dakhil, S.R.2    Foster, N.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.